Plain-English translation of NCT07507513 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called SSGJ- to see if it can help people with moderate to severe ulcerative colitis—especially those whose disease hasn't responded well to other treatments or who depend on steroids. The study will give some people the medication at different dose levels while others receive a placebo (a fake injection), so researchers can compare how well the treatment works and whether it's safe.
Many people with ulcerative colitis don't respond well enough to current medications, become dependent on steroids, or can't tolerate their current treatments. This trial exists to find out if this new medication could offer hope for those patients.
You likely qualify if…
You likely don't qualify if…
You would receive subcutaneous injections (shots under the skin) of either the new medication at one of several dose levels or a placebo. The study involves multiple visits to the research clinic where your doctors will check how you're responding to the treatment, monitor your symptoms, and run blood tests to ensure your safety. Your participation would last several months, and you'll be randomly assigned to receive either the medication or placebo so researchers can fairly compare the results.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Enrollment target
~288 participants
Started
March 2026
Primary completion
February 2029
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qinghong Zhou
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.